UnknownNot applicableNCT05902039
MRI Study of Blood-brain Barrier Function in CADASIL
Studying Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University First Hospital
- Principal Investigator
- Chen Ling, PhD, PhD
- Intervention
- MRI(other)
- Enrollment
- 100 enrolled
- Eligibility
- 20-70 years · All sexes
- Timeline
- 2021 – 2025
Study locations (1)
- Peking University First Hospital, Beijing, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05902039 on ClinicalTrials.govOther trials for Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT05755997CERebrolysin In CADASILEver Neuro Pharma GmbH
- RECRUITINGNCT06148051AusCADASIL: An Australian Cohort of CADASILPerminder Sachdev
- RECRUITINGNCT06938100Genotype, Clinical Features and Imaging of Neuroradiological Abnormalities in CADASILFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNANCT06935578RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNCT05072483Natural History Study of CADASILNational Heart, Lung, and Blood Institute (NHLBI)